http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2005245004-B2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5723838cfc3775d34156e4604ba8d4d7 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-282 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05 |
filingDate | 2005-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2011-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a6f33792edba51217af955da6d2a306 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7c16fbc008132ae076f137ff1b932d58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30a9cc38f954e8cad74b54767c436f2c |
publicationDate | 2011-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | AU-2005245004-B2 |
titleOfInvention | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
abstract | The use of a GST-activated anticancer compound in the manufacture of a medicament for sensitizing a mammal, especially a human, to another anticancer therapy (that is, an anticancer therapy that is not treatment with a GST-activated anticancer compound - including chemotherapy, molecular targeted therapy, biologic therapy, and radiotherapy, each used as monotherapy or two or more used in combination), or for ameliorating a side effect of another anticancer therapy in a mammal, especially a human. Compositions containing a GST-activated anticancer compound for these uses. A method of sensitizing a mammal, especially a human, to another anticancer therapy, by administering a sensitizing effective amount of a GST activated anticancer compound. A method of ameliorating a side effect of another anticancer therapy in a mammal, especially a human, by administering an ameliorating effective amount of a GST activated anticancer compound. The GST activated anticancer compound is preferably a compound of US Patent No. 5,556,942, and more preferably canfosfamide, especially as the hydrochloride salt. |
priorityDate | 2004-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 384.